UY38907A - Compuestos derivados de 2–azaespiro[3.4]octano como agonistas de m4 y composiciones de los mismos - Google Patents

Compuestos derivados de 2–azaespiro[3.4]octano como agonistas de m4 y composiciones de los mismos

Info

Publication number
UY38907A
UY38907A UY0001038907A UY38907A UY38907A UY 38907 A UY38907 A UY 38907A UY 0001038907 A UY0001038907 A UY 0001038907A UY 38907 A UY38907 A UY 38907A UY 38907 A UY38907 A UY 38907A
Authority
UY
Uruguay
Prior art keywords
agonists
compositions
azaespiro
octane
same
Prior art date
Application number
UY0001038907A
Other languages
English (en)
Inventor
Xin Chen
Amy Calhoun
Kevin Matthew Gardinier
Edward Charles Hall
Keith Jendza
Nancy Labbe-Giguere
James Neef
Daniel Steven Palacios
Ming Qian
Kate Yaping Wang
Fan Yang
Michael David Shultz
Christopher G Thomson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY38907A publication Critical patent/UY38907A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan compuestos de acuerdo con la Fórmula (I) o su sal farmacéuticamente aceptable, en donde R1, R2, R3, R5, y R7 se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.
UY0001038907A 2019-10-09 2020-10-07 Compuestos derivados de 2–azaespiro[3.4]octano como agonistas de m4 y composiciones de los mismos UY38907A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962912986P 2019-10-09 2019-10-09

Publications (1)

Publication Number Publication Date
UY38907A true UY38907A (es) 2021-05-31

Family

ID=72944206

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038907A UY38907A (es) 2019-10-09 2020-10-07 Compuestos derivados de 2–azaespiro[3.4]octano como agonistas de m4 y composiciones de los mismos

Country Status (20)

Country Link
US (3) US11485742B2 (es)
EP (1) EP4041737A1 (es)
JP (1) JP7349567B2 (es)
KR (1) KR20220079608A (es)
CN (1) CN114555606A (es)
AR (1) AR120169A1 (es)
AU (1) AU2020364186B2 (es)
CA (1) CA3155589A1 (es)
CL (1) CL2022000892A1 (es)
CO (1) CO2022004391A2 (es)
CR (1) CR20220153A (es)
EC (1) ECSP22027784A (es)
IL (1) IL291600A (es)
JO (1) JOP20220084A1 (es)
MX (1) MX2022004215A (es)
PE (1) PE20221454A1 (es)
TW (1) TW202128703A (es)
UY (1) UY38907A (es)
WO (1) WO2021070091A1 (es)
ZA (1) ZA202202913B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041389A1 (en) * 2019-10-09 2022-08-17 Novartis AG 2-azaspiro[3.4]octane derivatives as m4 agonists
WO2024059249A1 (en) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
US7880007B2 (en) 2004-11-29 2011-02-01 Vertex Pharmaceuticals Incorporated Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
US8927715B2 (en) 2006-08-25 2015-01-06 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
CA2750777C (en) * 2009-01-26 2018-04-03 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US20130230459A1 (en) 2010-11-08 2013-09-05 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGluR2 PET LIGANDS
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
CN103732588B (zh) 2011-07-27 2016-10-12 南京奥昭生物科技有限公司 螺环分子作为蛋白激酶抑制剂
WO2014039489A1 (en) 2012-09-07 2014-03-13 Zoetis Llc Spirocyclic derivatives as antiparasitic agents
CA2883210C (en) 2012-09-18 2021-06-15 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
LT3102568T (lt) * 2014-02-06 2018-11-12 Heptares Therapeutics Limited Bicikliniai azo junginiai, kaip muskarino m1 receptorių agonistai
KR20170090422A (ko) 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB2540998A (en) 2015-08-04 2017-02-08 Phagenesis Ltd Catheter
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
BR112018075260A2 (pt) 2016-06-10 2019-03-12 Vitae Pharmaceuticals Inc inibidores da interação de menina-llm
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
FI3768669T3 (fi) 2018-03-23 2023-04-26 Pfizer Piperatsiiniatsaspirojohdannaisia
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2022551853A (ja) 2022-12-14
ECSP22027784A (es) 2022-05-31
AR120169A1 (es) 2022-02-02
AU2020364186B2 (en) 2023-11-30
AU2020364186A1 (en) 2022-04-21
IL291600A (en) 2022-05-01
CL2022000892A1 (es) 2023-01-20
PE20221454A1 (es) 2022-09-21
JP7349567B2 (ja) 2023-09-22
US11485742B2 (en) 2022-11-01
EP4041737A1 (en) 2022-08-17
CA3155589A1 (en) 2021-04-15
WO2021070091A1 (en) 2021-04-15
US20240140959A1 (en) 2024-05-02
TW202128703A (zh) 2021-08-01
US20210130365A1 (en) 2021-05-06
CO2022004391A2 (es) 2022-04-29
CR20220153A (es) 2022-05-03
JOP20220084A1 (ar) 2023-01-30
KR20220079608A (ko) 2022-06-13
US11820778B2 (en) 2023-11-21
MX2022004215A (es) 2022-05-03
ZA202202913B (en) 2023-06-28
CN114555606A (zh) 2022-05-27
US20220411435A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
BR112018007381A2 (pt) compostos úteis como imunomoduladores
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
PH12021550049A1 (en) Selective estrogen receptor degraders.
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
CO2019010804A2 (es) Derivados de indol n–sustituidos
MX2018002242A (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CL2020001817A1 (es) Moduladores del receptor c5a
MY197742A (en) Morphinan derivative
MA50093B1 (fr) Composé pentacyclique
BR112021026899A2 (pt) Compostos heterocíclicos
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
EA202091481A1 (ru) Замещенные алкиниленовые соединения в качестве противораковых агентов
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
CL2021003348A1 (es) Derivados de piridin–3–ilo.